03/07/2025
Tirzepatide, commonly known as Mounjaro®, is being introduced in a small number of GP practices as part of wider support for people living with obesity. It is only available to a limited number of patients in the first year, based on strict NHS criteria.
Eligibility includes a BMI of 40 or more and at least four serious weight-related health conditions. Patients must also take part in a structured support programme (wraparound care) including healthy eating and physical activity. There is no need to contact your GP practice - eligible patients will be contacted directly by their practice or the NHS.
This phased rollout follows updated guidance from the National Institute for Health and Care Excellence (NICE) and is part of a national staged programme aimed at improving health outcomes for people living with obesity and related conditions such as type 2 diabetes, high blood pressure and heart disease.
In the first year, Mounjaro® is only available to patients who have:
A BMI of 40 or more (adjusted for ethnicity)
At least four of the following health conditions (each of which has its own qualifying level of severity) - type 2 diabetes - high blood pressure - heart disease - obstructive sleep apnoea - abnormal blood fats (dyslipidemias)
Or where urgent weight loss is needed for critical surgery or treatment
If you're from a South Asian, Chinese, Middle Eastern, Black African or African-Caribbean background, the BMI threshold is slightly lower - 37.5 instead of 40.
We understand that it may feel frustrating or disappointing if you're not eligible for Mounjaro® at this time - even if you’ve been hoping for this kind of support. Not everyone will be eligible for medication right now. But this is not a reflection of your effort, your worth, or your need.
